Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Share News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arix Bioscience Investee Quench Bio Completes Series A Financing

Mon, 27th Jan 2020 14:33

(Alliance News) - Arix Bioscience PLC said that its investee Quench Bio has emerged from "stealth mode," after completing the Series A financing and bringing total committed funding to USD50 million.

"This follows a period of company creation, with seed investment and close involvement by Arix," the biotech investment company said.

Arix founded and seeded Quench Bio together with the US venture capital firm Atlas Venture Ltd in 2018 along with co-founders Mark Tebbe, chief technology officer, and Mike Nolan, head of biology.

In addition to Arix and Atlas, the healthcare investor RA Capital led the Series A and were joined by AbbVie Ventures.

Quench Bio's lead therapeutic approach centers on inhibiting the protein Gasdermin D, which has recently been discovered as a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis, the company said.

"This is at the cutting edge of contemporary drug development and a field of significant commercial interest by big pharma," Arix said.

Arix said Quench Bio has built a highly experienced leadership team, led by Chief Executive Officer Samantha Truex, the former chief business officer of Padlock Therapeutics Inc, which was acquired by US pharmaceutical company Bristol Myers Squibb in 2016.

Jonathan Tobin, investment director at Arix and board director of Quench Bio, said: "We are excited and privileged to work alongside such a distinguished team of entrepreneurs and co-investors to develop first-in-class medicines that could make a major difference to patients suffering from chronic inflammatory and auto-immune diseases."

Arix Bioscience shares were trading 0.4% lower in London at 95.60 pence each on Monday.

By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
29 Mar 2021 15:13

EXECUTIVE CHANGES: F&C Investment Trust hires CBI chief economist

EXECUTIVE CHANGES: F&C Investment Trust hires CBI chief economist

Read more
24 Mar 2021 16:44

TRADING UPDATES: Arden Partners to return to annual profitability

TRADING UPDATES: Arden Partners to return to annual profitability

Read more
22 Mar 2021 11:40

IN BRIEF: Arix Bioscience launches GBP25 million buyback programme

IN BRIEF: Arix Bioscience launches GBP25 million buyback programme

Read more
15 Mar 2021 21:44

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

Read more
10 Mar 2021 19:23

IN BRIEF: Arix responds to Acacia's letter on executive changes

IN BRIEF: Arix responds to Acacia's letter on executive changes

Read more
9 Mar 2021 21:21

IN BRIEF: Arix shareholder Acacia calls for executive shake up

IN BRIEF: Arix shareholder Acacia calls for executive shake up

Read more
9 Mar 2021 12:03

IN BRIEF: Arix Bioscience swings to profit in 2020; founds Twelve Bio

IN BRIEF: Arix Bioscience swings to profit in 2020; founds Twelve Bio

Read more
26 Feb 2021 17:14

EXECUTIVE CHANGES: Marlowe Poaches From Fullers; RM Promotes To CEO

EXECUTIVE CHANGES: Marlowe Poaches From Fullers; RM Promotes To CEO

Read more
10 Feb 2021 09:41

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Read more
26 Jan 2021 10:21

Derwent London Picks Former JP Morgan London Executive For Chair

Derwent London Picks Former JP Morgan London Executive For Chair

Read more
18 Jan 2021 11:00

Arix Bioscience Managing Director Tobin To Resign In March

Arix Bioscience Managing Director Tobin To Resign In March

Read more
13 Jan 2021 07:01

IN BRIEF: Arix Bioscience Closes Public Offering Of Shares

IN BRIEF: Arix Bioscience Closes Public Offering Of Shares

Read more
6 Jan 2021 20:18

IN BRIEF: Arix Bioscience Says Sickle Cell Drug IMR-687 Well Tolerated

IN BRIEF: Arix Bioscience Says Sickle Cell Drug IMR-687 Well Tolerated

Read more
21 Dec 2020 17:07

DIRECTOR DEALINGS: Arix Bioscience Chair Buys GBP377,000 In Shares

DIRECTOR DEALINGS: Arix Bioscience Chair Buys GBP377,000 In Shares

Read more
8 Sep 2020 17:49

IN BRIEF: Arix Bioscience Shakes Off Virus To Post Promising Interim

IN BRIEF: Arix Bioscience Shakes Off Virus To Post Promising Interim

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.